[uam_ad id="317182"]

RIO DE JANEIRO, BRAZIL - The Covaxx, a Covid-19 vaccine under the management of the American biopharmaceutical company United Biomedical, should begin trials in Brazil in January. The phase 2 and 3 trials will be coordinated by Dasa laboratory, specialized in diagnostic medicine.

The plan is to submit an authorization request to ANVISA, Brazil's National Health Regulatory Agency, to conduct the study in early 2021. Authorization by the agency should take no more than 72 hours in the current pandemic scenario. As soon as it is cleared, this will be the fifth vaccine in phase 3 (the most advanced . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?